Ventyx Biosciences (NASDAQ:VTYX) Sets New 1-Year High - Here's What Happened

Key Points

• Ventyx Biosciences stock reached a new 52-week high of $7.48, marking a significant increase from its previous close of $3.86, with over 45 million shares traded.
• Analysts have rated VTYX with a consensus of "Hold", while the company's price target is set at $7.50, following mixed ratings from various analysts.
• Institutional investors own 97.88% of Ventyx Biosciences' stock, indicating strong interest from hedge funds and increasing stakes in the company during recent quarters.

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $7.48 and last traded at $7.41, with a volume of 45561441 shares. The stock had previously closed at $3.86.

Analyst Ratings Changes

VTYX has been the subject of a number of recent analyst reports. Wall Street Zen raised Ventyx Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $7.50.

Ventyx Biosciences Trading Up 82.8%

The firm has a market cap of $503.31 million, a price-to-earnings ratio of -4.21 and a beta of 1.01. The firm has a 50 day moving average price of $2.96 and a 200-day moving average price of $2.33.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.07. As a group, equities analysts expect that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in VTYX. Affinity Asset Advisors LLC acquired a new position in shares of Ventyx Biosciences during the 2nd quarter worth $9,707,000. Marshall Wace LLP purchased a new stake in Ventyx Biosciences during the 2nd quarter worth about $5,129,000. Redmile Group LLC grew its holdings in Ventyx Biosciences by 1,164.1% in the 1st quarter. Redmile Group LLC now owns 1,569,793 shares of the company's stock valued at $1,805,000 after buying an additional 1,445,615 shares during the period. Monaco Asset Management SAM grew its holdings in Ventyx Biosciences by 372.7% in the 1st quarter. Monaco Asset Management SAM now owns 1,134,444 shares of the company's stock valued at $1,305,000 after buying an additional 894,444 shares during the period. Finally, AQR Capital Management LLC grew its holdings in Ventyx Biosciences by 925.6% in the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company's stock valued at $1,012,000 after buying an additional 794,401 shares during the period. Institutional investors and hedge funds own 97.88% of the company's stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.